TY - JOUR
T1 - Use of photodynamic therapy for treatment of ocular malignancies
AU - Kim, R. Y.
AU - Young, L. H.Y.
N1 - Funding Information:
This article was funded by Heed Fellowship (RYK); NIH EY10975 (LHY); Massachusetts Lions Eye Research Fund, Inc. (LHY); Cancer Research Institute (LHY).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - Photodynamic therapy is a treatment modality using activation of a photosensitizer with light of an appropriate wavelength. Ocular tumors are good candidates for such clinical application because of excellent visualization of tumors regardless of their locations. Early clinical studies with hematoporphyrin derivatives, with their skin photosensitivity and lack of tissue penetration, have been less than convincing that PDT could replace existing conventional ocular tumor treatments. With a surge of second generation photosensitizers with much improved photophysical properties, however, experimental studies in animal models of iris and choroidal melanoma have been performed with encouraging results. PDT for retinoblastoma, however, needs further investigation, requiring a good animal model. With further refinements in PDT, such as improving tissue localization of the photosensitizers and the light delivery system, PDT may provide an additional treatment option for ocular malignancies.
AB - Photodynamic therapy is a treatment modality using activation of a photosensitizer with light of an appropriate wavelength. Ocular tumors are good candidates for such clinical application because of excellent visualization of tumors regardless of their locations. Early clinical studies with hematoporphyrin derivatives, with their skin photosensitivity and lack of tissue penetration, have been less than convincing that PDT could replace existing conventional ocular tumor treatments. With a surge of second generation photosensitizers with much improved photophysical properties, however, experimental studies in animal models of iris and choroidal melanoma have been performed with encouraging results. PDT for retinoblastoma, however, needs further investigation, requiring a good animal model. With further refinements in PDT, such as improving tissue localization of the photosensitizers and the light delivery system, PDT may provide an additional treatment option for ocular malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0032788171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032788171&partnerID=8YFLogxK
U2 - 10.1016/S0896-1549(05)70093-6
DO - 10.1016/S0896-1549(05)70093-6
M3 - Article
AN - SCOPUS:0032788171
SN - 0896-1549
VL - 12
SP - 167
EP - 176
JO - Ophthalmology Clinics of North America
JF - Ophthalmology Clinics of North America
IS - 2
ER -